B. Lynne Parshall's Insider Trades & SAST Disclosures
B. Lynne Parshall's most recent trade in Cytokinetics Inc was a trade of 5,000 Common Stock done at an average price of $21.6 . Disclosure was reported to the exchange on Sept. 9, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern B. Lynne Parshall.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.61 per share. | 09 Sep 2024 | 5,000 | 25,600 (0%) | 0% | 21.6 | 108,050 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 5,000 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 54.92 per share. | 09 Sep 2024 | 5,000 | 20,600 (0%) | 0% | 54.9 | 274,600 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.61 per share. | 26 Aug 2024 | 5,000 | 25,600 (0%) | 0% | 21.6 | 108,050 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 5,000 | 5,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 57.26 per share. | 26 Aug 2024 | 5,000 | 20,600 (0%) | 0% | 57.3 | 286,300 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 55.20 per share. | 12 Aug 2024 | 5,000 | 20,600 (0%) | 0% | 55.2 | 276,000 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.61 per share. | 12 Aug 2024 | 5,000 | 25,600 (0%) | 0% | 21.6 | 108,050 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 5,000 | 10,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 59.84 per share. | 29 Jul 2024 | 5,000 | 20,600 (0%) | 0% | 59.8 | 299,200 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2024 | 5,000 | 15,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.61 per share. | 29 Jul 2024 | 5,000 | 25,600 (0%) | 0% | 21.6 | 108,050 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 55.82 per share. | 15 Jul 2024 | 5,000 | 20,600 (0%) | 0% | 55.8 | 279,100 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.68 per share. | 15 Jul 2024 | 5,000 | 25,600 (0%) | 0% | 10.7 | 53,400 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 5,000 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 4,677 | 4,079 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 4,677 | 87,265 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 10,111 | 10,111 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 5,000 | 5,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 54.22 per share. | 01 Jul 2024 | 5,000 | 20,600 (0%) | 0% | 54.2 | 271,100 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.68 per share. | 01 Jul 2024 | 5,000 | 25,600 (0%) | 0% | 10.7 | 53,400 | Common Stock |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 4,079 | 8,756 | - | - | Restricted Stock Unit | |
| Foghorn Therapeutics Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.68 per share. | 17 Jun 2024 | 5,000 | 25,600 (0%) | 0% | 10.7 | 53,400 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2024 | 5,000 | 10,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 52.55 per share. | 17 Jun 2024 | 5,000 | 20,600 (0%) | 0% | 52.6 | 262,750 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 5,000 | 15,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 48.64 per share. | 03 Jun 2024 | 5,000 | 15,600 (0%) | 0% | 48.6 | 243,200 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.68 per share. | 03 Jun 2024 | 5,000 | 20,600 (0%) | 0% | 10.7 | 53,400 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 5,600 | 20,600 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 3,636 | 3,636 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Ionis Pharmaceuticals Inc | Parshall B. Lynne | Director | Sale of securities on an exchange or to another person at price $ 50.23 per share. | 26 Dec 2023 | 50,000 | 82,588 (0%) | 0% | 50.2 | 2,511,515 | Common Stock |
| Ionis Pharmaceuticals Inc | B. Parshall Lynne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2023 | 50,000 | 42,525 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | B. Parshall Lynne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 26 Dec 2023 | 50,000 | 132,588 (0%) | 0% | 47.3 | 2,367,000 | Common Stock |
| Ionis Pharmaceuticals Inc | B. Parshall Lynne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 26 Dec 2023 | 42,525 | 125,113 (0%) | 0% | 47.3 | 2,013,134 | Common Stock |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 50.19 per share. | 26 Dec 2023 | 42,525 | 82,588 (0%) | 0% | 50.2 | 2,134,223 | Common Stock |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2023 | 42,525 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Parshall B. Lynne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 26 Dec 2023 | 25,113 | 107,701 (0%) | 0% | 47.3 | 1,188,849 | Common Stock |
| Ionis Pharmaceuticals Inc | Lynne Parshall B. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2023 | 25,113 | 92,525 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Lynne B. Parshall | Director | Sale of securities on an exchange or to another person at price $ 51.46 per share. | 26 Dec 2023 | 25,113 | 82,588 (0%) | 0% | 51.5 | 1,292,390 | Common Stock |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 5,333 | 4,677 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 5,333 | 92,588 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 1,777 | 87,255 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 1,777 | 10,010 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 10,321 | 10,321 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 4,677 | 11,787 | - | - | Restricted Stock Unit | |
| Foghorn Therapeutics Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 10,000 | 10,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 5,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 52.79 per share. | 01 Sep 2022 | 30,296 | 10,000 (0%) | 0% | 52.8 | 1,599,326 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 01 Sep 2022 | 20,000 | 35,714 (0%) | 0% | 9.5 | 189,000 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 20,000 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 5,714 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.75 per share. | 01 Sep 2022 | 5,714 | 15,714 (0%) | 0% | 8.8 | 49,998 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 4,582 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.82 per share. | 01 Sep 2022 | 4,582 | 40,296 (0%) | 0% | 6.8 | 31,249 | Common Stock |
| Foghorn Therapeutics Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 32,000 | 32,000 | - | - | Stock Options (Right to buy) | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 5,333 | 9,775 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 5,333 | 82,813 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 2,665 | 85,478 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 2,665 | 7,110 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 12,000 | 12,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 5,333 | 15,108 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 5,754 | 9,775 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 5,754 | 79,132 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.12 per share. | 18 Jan 2022 | 1,652 | 77,480 (0%) | 0% | 30.1 | 49,758 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 05 Nov 2021 | 20,000 | 25,000 (0%) | 0% | 14.3 | 285,000 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 20,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 05 Nov 2021 | 20,000 | 5,000 (0%) | 0% | 40 | 800,000 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 4,166 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 05 Nov 2021 | 4,166 | 5,000 (0%) | 0% | 40 | 166,640 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.78 per share. | 05 Nov 2021 | 4,166 | 9,166 (0%) | 0% | 6.8 | 28,245 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 4,032 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 05 Nov 2021 | 4,032 | 5,000 (0%) | 0% | 40 | 161,280 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.40 per share. | 05 Nov 2021 | 4,032 | 9,032 (0%) | 0% | 12.4 | 49,997 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 2,798 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 05 Nov 2021 | 2,798 | 5,000 (0%) | 0% | 40 | 111,920 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.84 per share. | 05 Nov 2021 | 2,798 | 7,798 (0%) | 0% | 6.8 | 19,138 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2021 | 8,333 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 35.73 per share. | 19 Oct 2021 | 8,333 | 5,000 (0%) | 0% | 35.7 | 297,774 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.60 per share. | 19 Oct 2021 | 8,333 | 13,333 (0%) | 0% | 6.6 | 54,998 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 35.73 per share. | 19 Oct 2021 | 1,999 | 5,000 (0%) | 0% | 35.7 | 71,433 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.84 per share. | 19 Oct 2021 | 1,999 | 6,999 (0%) | 0% | 6.8 | 13,673 | Common Stock |
| Cytokinetics Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2021 | 1,999 | 2,798 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 5,333 | 18,196 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 5,333 | 70,711 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 1,778 | 15,529 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 1,778 | 73,378 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 889 | 17,307 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 889 | 71,600 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 12,000 | 12,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 5,333 | 23,529 | - | - | Restricted Stock Unit | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 10,000 | 10,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 5,000 | 5,000 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 10,655 | 68,119 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 10,655 | 5,754 | - | - | Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.28 per share. | 15 Jan 2021 | 2,741 | 65,378 (0%) | 0% | 61.3 | 167,968 | Common Stock |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 23 Dec 2020 | 10,000 | 57,464 (0%) | 0% | 60 | 600,000 | Common Stock |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2020 | 3,590 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.87 per share. | 25 Nov 2020 | 3,590 | 71,054 (0%) | 0% | 39.9 | 143,133 | Common Stock |
| Ionis Pharmaceuticals Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 50.05 per share. | 25 Nov 2020 | 3,590 | 67,464 (0%) | 0% | 50.1 | 179,680 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges